SWITCHING FROM STATIN MONOTHERAPY TO EZETIMIBE/SIMVASTATIN OR ROSUVASTATIN MODIFIES THE RELATIONSHIPS BETWEEN APOLIPOPROTEIN B, LDL CHOLESTEROL, ANC NON-HDL CHOLETEROL IN PATIENTS AT HIGH RISK OF CORONARY DISEASE

Maurizio Averna, Luc Missault, Margus Viigimaa, Philippe Brudi, Arvind Shah, Qian Dong, Arvind Shah, Margus Viigimaa, Margus Viigimaa, Amy O. Johnson-Levonas, Helena Vaverkova, Michel Farnier, Maurizio Averna

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

OBJECTIVE:To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL-C in high-risk patients treated with lipid-lowering therapy.DESIGN AND METHODS:This post-hoc analysis calculated LDL-C and non-HDL-C levels corresponding to an Apo B of 0.9 g/L following treatment with 1) statin monotherapy (baseline) and 2) ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg (study end). The percentages of patients reaching LDL-C, non-HDL-C, and Apo B targets were calculated at study end.RESULTS:After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Only slightly >50% of the patients who reached minimum recommended LDL-C or non-HDL-C at study end also had an Apo B level <0.9 g/L with both treatments.CONCLUSION:The use of Apo B for monitoring the efficacy of lipid-altering therapy would likely lead to more stringent criteria for lipid lowering.
Original languageEnglish
Pages (from-to)627-634
Number of pages8
JournalClinical Biochemistry
Volume44
Publication statusPublished - 2011

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'SWITCHING FROM STATIN MONOTHERAPY TO EZETIMIBE/SIMVASTATIN OR ROSUVASTATIN MODIFIES THE RELATIONSHIPS BETWEEN APOLIPOPROTEIN B, LDL CHOLESTEROL, ANC NON-HDL CHOLETEROL IN PATIENTS AT HIGH RISK OF CORONARY DISEASE'. Together they form a unique fingerprint.

Cite this